Order Article Reprints

Chung S-Y, Hung Y-P, Pan Y-R, Chang Y-C, Wu C-E, Hsu DS-S, Chang PM-H, Lu M-L, Huang C-YF, Su Y, et al. Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. Biomedicines. 2021; 9(8):885. https://doi.org/10.3390/biomedicines9080885

Chung, Shin-Yi, Yi-Ping Hung, Yi-Ru Pan, Yu-Chan Chang, Chiao-En Wu, Dennis Shin-Shian Hsu, Peter Mu-Hsin Chang, Meng-Lun Lu, Chi-Ying F. Huang, Yeu Su, and et al. 2021. "Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway" Biomedicines 9, no. 8: 885. https://doi.org/10.3390/biomedicines9080885

Chung, S.-Y., Hung, Y.-P., Pan, Y.-R., Chang, Y.-C., Wu, C.-E., Hsu, D. S.-S., Chang, P. M.-H., Lu, M.-L., Huang, C.-Y. F., Su, Y., Hsiao, M., Yeh, C.-N., & Chen, M.-H. (2021). Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. Biomedicines, 9(8), 885. https://doi.org/10.3390/biomedicines9080885